Caris Life Sciences, Inc.
CAI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $412,260 | $306,128 | $258,485 | $294,013 |
| % Growth | 34.7% | 18.4% | -12.1% | – |
| Cost of Goods Sold | $233,478 | $216,818 | $178,463 | $109,856 |
| Gross Profit | $178,782 | $89,310 | $80,022 | $184,157 |
| % Margin | 43.4% | 29.2% | 31% | 62.6% |
| R&D Expenses | $113,916 | $116,883 | $101,268 | $0 |
| G&A Expenses | $173,559 | $151,953 | $156,154 | $27,312 |
| SG&A Expenses | $321,860 | $291,478 | $294,510 | $27,312 |
| Sales & Mktg Exp. | $148,301 | $139,525 | $138,356 | $0 |
| Other Operating Expenses | $128 | $500 | $0 | $17,758 |
| Operating Expenses | $435,904 | $408,861 | $395,778 | $45,070 |
| Operating Income | -$257,122 | -$319,551 | -$315,756 | $139,087 |
| % Margin | -62.4% | -104.4% | -122.2% | 47.3% |
| Other Income/Exp. Net | -$24,768 | -$21,864 | -$5,071 | -$109,554 |
| Pre-Tax Income | -$281,890 | -$341,415 | -$320,827 | $29,533 |
| Tax Expense | $0 | $0 | $0 | $1,800 |
| Net Income | -$281,890 | -$341,415 | -$320,827 | $27,733 |
| % Margin | -68.4% | -111.5% | -124.1% | 9.4% |
| EPS | -2.7 | -1.82 | -1.57 | 1.55 |
| % Growth | -48.4% | -15.9% | -201.3% | – |
| EPS Diluted | -2.7 | -1.82 | -1.57 | 1.55 |
| Weighted Avg Shares Out | 254,663 | 254,663 | 254,789 | 17,949 |
| Weighted Avg Shares Out Dil | 254,663 | 254,663 | 254,789 | 17,949 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7,122 | $11,258 | $947 | $0 |
| Interest Expense | $50,025 | $31,610 | $26,680 | $61,565 |
| Depreciation & Amortization | $48,913 | $49,001 | $48,253 | $110,650 |
| EBITDA | -$182,952 | -$260,804 | -$245,894 | $254,457 |
| % Margin | -44.4% | -85.2% | -95.1% | 86.5% |